EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of ophthalmic products for the treatment of eye diseases. The company was founded in 1987 and is headquartered in Watertown, Massachusetts. The company was previously known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018.
EyePoint Pharmaceuticals, Inc. develops sustained-release drug delivery systems that can be implanted or injected directly into the eye. The company's products are designed to provide targeted treatment to the back of the eye for various eye diseases such as macular edema, diabetic retinopathy, and uveitis. The company's flagship product is DEXYCU, which is a long-acting corticosteroid for the treatment of postoperative inflammation. The company also has several other products in its pipeline, including YUTIQ for uveitis and DEXYCU for diabetic macular edema.
EyePoint Pharmaceuticals, Inc. went public in 2000 and is traded on the NASDAQ under the symbol "EYPT". The company completed a reverse stock split in 2020 to increase the per-share price and maintain its listing on the NASDAQ. EyePoint has partnerships and collaborations with other companies in the industry, including Bausch Health Companies, Inc. and Ocumension Therapeutics.
EyePoint Pharmaceuticals, Inc. has been recognized for its innovation in drug delivery technology, receiving multiple patents for its Durasert and Tethadur sustained-release technologies. The company has also been awarded grants from the National Institutes of Health to support its research and development efforts.
In addition to its focus on developing and commercializing ophthalmic products, EyePoint Pharmaceuticals, Inc. is committed to improving patient outcomes and quality of life. The company partners with patient advocacy organizations and supports initiatives that promote awareness and education about eye diseases and treatment options.